Neuralstem, Inc., a biopharmaceutical company, focuses on the development and commercialization of treatments for central nervous system disease based on transplanting human neural stem cells and the use of small molecule drugs. Its stem cell technology enables the isolation and expansion of human neural stem cells from various areas of the developing human brain and spinal cord enabling the generation of physiologically relevant human neurons. The company is developing a Phase I clinical trial product for the treatment of amyotrophic lateral sclerosis (ALS). It is also developing products targeting central nervous system conditions through its cell therapy platform, including spinal cord injury, ischemic spastic paraplegia, and chronic stroke. In addition, the company is evaluating NSI-189, a neurogenic small molecule compound, which is in a Phase Ib clinical trial for the treatment of major depressive disorder, as well as for the treatment of chronic traumatic encephalopathy, Alzheimer's disease, anxiety, and post-traumatic stress disorder. Neuralstem, Inc. was founded in 1996 and is headquartered in Rockville, Maryland.